Previous Issue - Issue 46
Issue 46 | 2022
- Foreword
- Strategy
- Research & Development
- Clinical Trials
- Manufacturing
- Information Technology
- Advertorials Go to Digital Magazine
Issue 46
PREVIOUS ISSUE
Strategy
2022 TRENDS IN PHARMA MARKETING
Its been nearly two years since the outbreak of COVID began and were still in the midst of enormous disruptions to the worlds economies businesses education and peoples lives
Responsible Growth
Sustainability today is an important agenda for most organisations globally Across the board organisations are increasingly realising that sustainability is a critical parameter to define competitiveness and gain the trust and confidence of all stakeholders
BRIGHT FUTURE FOR ASIA M&A
The past two years have shone a bright light on the global pharmaceutical industry Perhaps more so than ever before the worlds eyes have been watching closely what may come and of course the next blockbuster product
Research & Development
COVID-19
WHERE ARE WE HEADING IN 2022?
COVID has posed an unprecedented threat to the health and economy globally since its first detection in December with more than million cases and million deaths as of February
Proposome, an Efficient and Safe Topical Formulation
Topical delivery is the most acceptable route for treating skin conditions as it provides localized and fast effects
Mathematical Modelling of Gene Expression
A toolbox for treatment design targeting modulation of gene networks dynamics
Despite all recent advances of molecular biology and imaging techniques treatment designs based on pharmaceuticals still need enhancement to improve prognostics of patients while reducing the severity of side effects
Clinical Trials
THE AGGREGATE SAFETY ASSESSMENT PLAN
A valuable tool for clinical trial safety planning
Recently a Drug Information Association American Statistical Associationsponsored Interdisciplinary Safety Evaluation working group published a recommended approach to the aggregate assessment of clinical trial safety data
Manufacturing
IMCD
A global leader in speciality chemicals and ingredients
The IMCD Group is a global leader in the formulation sales and distribution of speciality chemicals and ingredients As the Pharmaceuticals Business Group our goal is to advance ideas for a healthy future
VACCINES AGAINST SARS-COV-2
Current situation and future perspectives
As a rule of thumb in epidemiology the world faces a pandemic once every years The previous one was the Spanish flu in At the end of World War I a new strain of the influenza virus HN broke out in the United States
Information Technology
DRIVEN BY DATA
A ROADMAP TO BIOPHARMA’S DIGITAL FUTURE
Despite great effort and expense implementing datadriven business models and processes the biopharma industrys attempts to digitally transform operations are returning mixed results
